Why did you use clinical-grade molecules from originally licensed drugs in your research instead of research-grade molecules?

For analytical research it is critical to evaluate originally licensed drugs rather than research grade molecule as the level of complexity and of impurities can be totally different, thus lacking a proper validation for analytical method development.

What challenges did you face in sourcing small units of licensed drugs?

For analytical methods development, full drugs aliquots are unnecessary, while we prefer sample diversity which exposes our methodologies to several scenarios, demonstrating their robustness. Obtaining small aliquots it was impossible and expensive before finding out the services provided by Evidentic, and we have now the possibility to expand our biopharmaceutical library.

How did Evidentic services support you to streamline your research project?

Evidentic helped our research providing access to products not included in their stock in a timely manner, and they guarantee that sample integrity was preserved during aliquoting and transportation. In this way, our analytical development can be based on samples very close to what is injected into patients.

Would you agree that Evidentic speeded up your research?

More than speeding up our research, Evidentic team allowed us to plan and design experiments we were not able to perform before, opening up to new possibilities and surely more findings and novel methodologies that might be beneficial to the whole biopharma community.

What was your overall experience with Evidentic?

The whole Evidentic team did a great job, worked hard to meet our needs in a very intense phase at NIBRT, kept us updated during the whole process and managed the delivery fast and easy. The results of our research with the clinical-grade molecules procured by Evidentic will be published in some peer-reviewed journals. I cannot recommend more the team at Evidentic for their kindness and effort in understanding our queries, in a spirit of a true collaboration rather than a standard customer-vendor relationship.

Thank you very much, Sara, for taking the time for this interview.